Loading organizations...
§ Private Profile · Waltham, MA, USA
Clinical-stage biotech company developing precision cardiovascular and cardio-renal therapies for patients at high risk of adverse events.
Corvidia Therapeutics is a Boston, Massachusetts-based clinical-stage biotechnology company that develops precision cardiovascular and cardio-renal therapies using functional genomics to identify specific disease pathways. The organization leverages genome-guided approaches to create targeted treatments for high-risk populations with unique genetic susceptibilities, advancing clinical assets such as its lead monoclonal antibody candidate ziltivekimab. Originally launched as a strategic spinout from AstraZeneca's Emerging Innovations Unit, the enterprise subsequently secured a $26 million Series A funding round in 2016. This early capitalization was backed by prominent venture capital firms including Sofinnova Partners and Apple Tree Partners. In June 2020, pharmaceutical corporation Novo Nordisk acquired the business for a total deal value of $2.1 billion, which included an initial upfront payment of $725 million. Corvidia was founded in 2015 by Michael Davidson, Matt Devalaraja, Rahul Kakkar, and Ram Aiyar.
Corvidia has raised $86.0M across 2 funding rounds.
Corvidia has raised $86.0M in total across 2 funding rounds.
Corvidia has raised $86.0M in total across 2 funding rounds.
Corvidia's investors include Karim Helmy, Andera Partners, Apple Tree Partners, Cormorant Asset Management, Fresenius Medical Care Ventures, HBM Healthcare Investments, MedImmune, Sofinnova Partners, Seth Harrison, Graziano Seghezzi.
Corvidia has raised $86.0M across 2 funding rounds. Most recently, it raised $60.0M Series B in April 2018.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 25, 2018 | $60M Series B | Karim Helmy | Andera Partners, Apple Tree Partners, Cormorant Asset Management, Fresenius Medical Care Ventures, HBM Healthcare Investments, MedImmune, Sofinnova Partners | Announced |
| Feb 17, 2016 | $26M Series A | Seth Harrison, Graziano Seghezzi | — | Announced |